Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BCMA CAR-T in Refractory Generalized Myasthenia Gravis
NCT06371040Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BG2205 in myasthenia gravis (MG). Primary endpoint: Frequency, type, and severity of adverse events at 4 weeks. Started Jul 2024; status: recruiting.
02
Drugs
BG2205
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06371040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371040.